Synthetic Immune Receptor, A Next Generation CAR-T Platform
- Describing the current challenges facing cell therapy
- Describing the reasons why CAR-T therapies have failed and especially in solid tumors
- Introducing Synthetic Immune Receptor (SIR), a next generation HLA-independent TCR platform and describing the activity of SIR against solid tumors and blood cancers